These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 25868389)

  • 1. Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis.
    Chitikova Z; Pusztaszeri M; Makhlouf AM; Berczy M; Delucinge-Vivier C; Triponez F; Meyer P; Philippe J; Dibner C
    Oncotarget; 2015 May; 6(13):10978-93. PubMed ID: 25868389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a Potential Prognostic Matrix for Papillary Thyroid Cancer that Assesses Age, Tumor Size, Transforming Growth Factor-β, and BRAFV600E Mutation.
    Wang P; Lun Y; Fu Y; Wang F; Zhao S; Wang Y; Hou X
    Oncol Res Treat; 2017; 40(10):586-592. PubMed ID: 28892804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [BRAF initiating mutations in the papillary thyroid carcinoma].
    Rusinek D; Gubała E
    Endokrynol Pol; 2006; 57(4):438-44. PubMed ID: 17006850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of CHEK1, SLC26A4, c-KIT, TPO and TG as new biomarkers for human follicular thyroid carcinoma.
    Makhlouf AM; Chitikova Z; Pusztaszeri M; Berczy M; Delucinge-Vivier C; Triponez F; Meyer P; Philippe J; Dibner C
    Oncotarget; 2016 Jul; 7(29):45776-45788. PubMed ID: 27329729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An investigation of BRAF mutation in papillary thyroid carcinoma and its clinical value].
    Gong RX; Zhou Y; Luo SH; Zhang L; Zhou B
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Jun; 26(3):310-3. PubMed ID: 19504446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement.
    Pizzolanti G; Russo L; Richiusa P; Bronte V; Nuara RB; Rodolico V; Amato MC; Smeraldi L; Sisto PS; Nucera M; Bommarito A; Citarrella R; Lo Coco R; Cabibi D; Lo Coco A; Frasca F; Gulotta G; Latteri MA; Modica G; Galluzzo A; Giordano C
    Thyroid; 2007 Nov; 17(11):1109-15. PubMed ID: 17727338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.
    Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN
    Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules.
    Finley DJ; Arora N; Zhu B; Gallagher L; Fahey TJ
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3214-23. PubMed ID: 15240595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology.
    Moon HJ; Kwak JY; Kim EK; Choi JR; Hong SW; Kim MJ; Son EJ
    Ann Surg Oncol; 2009 Nov; 16(11):3125-31. PubMed ID: 19644722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma.
    Hawthorn L; Stein L; Varma R; Wiseman S; Loree T; Tan D
    Head Neck; 2004 Dec; 26(12):1069-83. PubMed ID: 15515157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genome-Wide Expression Screening Discloses Long Noncoding RNAs Involved in Thyroid Carcinogenesis.
    Liyanarachchi S; Li W; Yan P; Bundschuh R; Brock P; Senter L; Ringel MD; de la Chapelle A; He H
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4005-4013. PubMed ID: 27459529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
    Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
    Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
    Albarel F; Conte-Devolx B; Oliver C
    Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of the novel tumor-suppressor gene CCDC67 in papillary thyroid carcinoma.
    Yin DT; Xu J; Lei M; Li H; Wang Y; Liu Z; Zhou Y; Xing M
    Oncotarget; 2016 Feb; 7(5):5830-41. PubMed ID: 26716505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
    Lee EK; Chung KW; Yang SK; Park MJ; Min HS; Kim SW; Kang HS
    Anticancer Res; 2013 Nov; 33(11):4833-9. PubMed ID: 24222120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medullary and papillary carcinoma of the thyroid gland occurring as a collision tumour: report of three cases with molecular analysis and review of the literature.
    Rossi S; Fugazzola L; De Pasquale L; Braidotti P; Cirello V; Beck-Peccoz P; Bosari S; Bastagli A
    Endocr Relat Cancer; 2005 Jun; 12(2):281-9. PubMed ID: 15947103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
    Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.